Background: ERRa is an orphan member of the nuclear hormone receptor superfamily, which acts as a transcription factor and is involved in various metabolic processes. ERRa is also highly expressed in ossification zones during mouse development as well as in human bones and cell lines. Previous data have shown that this receptor up-modulates the expression of osteopontin, which acts as an inhibitor of bone mineralization and whose absence results in resistance to ovariectomy-induced bone loss. Altogether this suggests that ERRa may negatively regulate bone mass and could impact on bone fragility that occurs in the absence of estrogens.
Introduction
Bone is a highly dynamic tissue subjected to active remodeling, an equilibrium between construction by osteoblasts and resorption by osteoclasts. Osteoblast are derived from mesenchymal stem cells (MSCs) and their differentiation is promoted by various factors such as the transcription factors Osterix and Runx2 [1] [2] [3] . Mature osteoblasts express receptor activator of nuclear factor-kB ligand (RANKL), a protein that will signal through RANK, a member of the tumor necrosis factor receptor superfamily present at the surface of pre-osteoclasts, and induce differentiation of these cells [4] [5] [6] [7] . On another hand, osteoblasts, as well as other cell types, also express and secrete osteoprotegerin (opg), a decoy receptor that traps RANKL in the extracellular milieu, preventing it from acting on pre-osteoclasts, and thus inhibiting the differentiation of osteoclasts [8, 9] .
Stability of bone remodeling also requires other diffusible factors among which estrogens are instrumental. This is particularly illustrated after menopause in aging women, when the fall of circulating level of estrogens leads to enhanced bone remodeling with an excessive resorption [10, 11] . The resulting osteoporosis syndrome is associated with an enhanced fracture risk. Various means are currently available to prevent and treat osteoporosis, most of which mainly aim at inhibiting the excess of bone resorption. These include for example the use of estrogens (natural or synthetic) or of bisphosphonate to reduce osteoclast differentiation or induce their apoptosis, respectively [11] .
The effects of estrogens are mediated by two estrogen receptors (ERs) a and b, which act as ligand-dependent transcription factors and belong to the nuclear receptor superfamily [12] . This family also comprises so-called orphan receptors, i.e. for which no ligand has been identified to date [13] . Estrogen-Receptor Related receptor a (ERRa) was among the first orphan receptors isolated, based on its sequence similarity to ERa [14, 15] . Despite this close proximity, ERRa does not bind estrogen nor any identified natural ligand [16] . ERRa is expressed in several tissues both during embryonic development and in the adult [17] . A number of studies have identified ERRa as a major actor in the regulation of energy metabolism in oxidative tissues such as heart or slow-twitch skeletal muscle [18, 19 for reviews] . This receptor is indeed involved in the regulation of energy uptake, storage and consumption as well as in mitochondrial biogenesis and function and cardiac response to stress. Most of these effects are thought to depend on the PGC-1a coactivator, with which ERRa physically interacts. High expression of ERRa in various human tumors (originating from such organ as breast, colon and ovary) correlates with a poor prognosis [reviewed in 20] . Proliferation of various cancer cell lines can be inhibited by a synthesis modulator of ERRa, but not by its mere siRNA-mediated knocking-down [21] . ERRa is highly expressed in all ossification zones during mouse development, as well as in osteoblastic lines and normal human bones [22] . Furthermore, a polymorphic variant of the human ERRa promoter has been associated with variable bone mineral density (BMD) in premenopausal women [23] . Although the molecular functions of ERRa in bone cells have not been determined, osteopontin (opn), an inhibitor of bone mineralization [24] [25] [26] [27] [28] [29] [30] , has been identified as a positive ERRa transcriptional target [31] [32] [33] .
Here, we show that ERRaKO female mice resist to age-induced bone loss and present a more elevated bone formation rate as compared to wild type animals. Remarkably, ERRa deficiency also conferred resistance to bone loss induced by estrogen withdrawal. Noteworthy, no phenotype was observed in the bones of ERRa-deficient males. ERRaKO originating MSCs displayed enhanced capacities to differentiate into osteoblasts, together with a lower opn expression, as compared to wt MSCs. Altogether our results reveal the role of ERRa in the control of bone density and suggest important cross talks between ERRa and hormonal signalling pathways in bone physiology.
Results and Discussion
ERRa Deficiency Affects Bone Aging in Female, but Not in Male, Mice
The structural parameters of cortical and trabecular bone were measured in the femur diaphysis and metaphysis, respectively, of wild type (wt) and ERRa knockout female mice at 14 and 24 weeks. Cortical bone mineral density (BMD) and thickness augmented with age in a similar manner in both genotypes ( Fig. 1A and B) . The trabecular mineral density (TMD) was slightly more elevated (but not statistically significant) in wt animals as compared to ERRaKO, but significantly increased with time in the latter genotype (Fig. 1C) . Lower trabecular bone volume (BV/TV; Fig. 1D ) and trabecular number (TbN; Fig. 1E ) were observed in ERRaKO animals relative to wt ones at 14 wk. Interestingly whereas these two parameters were significantly reduced at 24 wk in wt animals as an effect of age, no significant variation occurred in ERRaKO mice. These results indicate that ERRaKO female mice, although deficient in bone trabeculae at maturity (14 wk), are resistant to age-related bone loss. Strikingly no difference was observed in any of the structural parameters of both cortical and trabecular bone between wild type and mutant male mice (Table 1) , indicating a gender-dependent effect of the absence of ERRa.
The evolution of bone between wild type and ERRaKO females prompted us to examine the parameters of bone resorption and bone formation at 14 wk of age (i.e. before a significant difference could be observed between genotypes). Bone formation rate, which represent the activity of osteoblasts, was more elevated in ERRaKO females than in wt animals ( Fig. 2A) .
The surface occupied by osteoblasts was identical in both genotypes (Fig. 2B ). Serum markers of bone resorption (Cterminal fragment of collagen 1 [Ctx], indicative of osteoclast activity) were not different between wild type and mutant females, indicating that bone resorption was not affected by the ERRa deficiency (Fig. 2C) . Consistently, a comparable number of osteoclasts ( Fig. 2D) , spaning an identical relative surface ( Fig. 2E ) were detected in both strains.
Altogether this suggests that the resistance of ERRaKO animals to age-induced bone loss could be due to an enhanced osteoblastic activity, and not to variation in osteoclast-related parameters. 
ERRa Negatively Regulates Osteoblast Differentiation
We thus analyzed the capacities of ERRaKO bone marrow mesenchymal cells to differentiate into osteoblasts ex vivo. After seven days in the appropriate medium, ERRa mutant cells produced a greater number of differentiation foci as estimated by alkaline phosphatase (ALP) staining (Fig. 3A) . This was accompanied by a higher mineralization activity, as revealed by von Kossa staining. As measured by quantitative PCR, the expression of various osteoblast differentiation markers, such as Runx-2, ALP or osteocalcin was found more elevated in ERRaKO cells by quantitative PCR. In contrast, opn, an ERRa target gene [31] [32] [33] , was less expressed in ERRaKO cells than in wild type cells. We also analyzed the kinetics of ALP expression during osteoblast differentiation (Fig. 3B) . In ERRaKO cells, ALP expression followed the same profile as in wild-type cells but was more elevated at each time point. The phenotype displayed by mutant cells was rescued by infection with an ERRa-encoding adenovirus (AdERRa; Fig. 3C ). Indeed, ALP staining was reduced by AdERRa infection as compared to cells infected with a GFPencoding adenovirus. AdERRa also reduced the mRNA expression of Runx-2, ALP and osteocalcin. This repression was not a general, non-specific phenomenon since osteopontin expression was enhanced by AdERRa, as expected. This suggests that the capacities of MSCs to differentiate into osteoblasts are enhanced in the absence of ERRa and that the number of precursor cells is not modified. The results above may reflect an effect of the absence of ERRa on osteoblast proliferation rather than on differentiation. To evaluate this hypothesis, we determined the growth capacities of bone marrow cells (Fig. 3D ). ERRaKO cells displayed identical growth rate as wild-type cells, as estimated by determining cell number after 3 and 7 days in culture. However, under these conditions, ERRaKO cells still displayed a higher ALP expression as measured by staining and mRNA expression. We thus concluded that the absence of ERRa enhanced the osteoblastic differentiation of bone marrow cells without modifying their proliferation capacities. This is in agreement with recent results showing that the inhibition of ERRa expression in mammary cells does not modify proliferation [21] . Our results are in contrast with previous data suggesting that ERRa promotes osteoblast differentiation [34] . However, it is worth noting that our study analyzed femoral mesenchymal cells (which form endochondral bone, i.e. requiring a cartilage anlagen) derived from ERRaKO mice, whereas Bonnelye et al. [34] used transiently transfected rat calvarial cells (which form intramembranous bone). These methodological differences might account for the apparent discrepancies found between both studies. In contrast, our data are in agreement with published results in which MSCs originating from an independent ERRaKO strain were found more prone to differentiate into osteoblasts [35] . Interestingly this report also show that ERRa concomitantly promotes adipocyte differentiation of MSCs, suggesting that the receptor modulates an inverse relationship between adipogenic and osteogenic commitment of MSCs. In further support of our data, it is also worth noting that the closely related ERRc receptor has recently been found to inhibit BMP2-induced osteoblast differentiation in vitro as well as BMP2-induced ectopic bone formation in vivo [36] . Elevated osteoblast differentiation ex vivo in the absence of ERRa is furthermore consistent with the more elevated BFR found in vivo in ERRaKO mice. Furthermore, opn has been shown to inhibit bone mineralization [24] [25] [26] [27] [28] [29] [30] . A lower level of opn expression in the absence of ERRa could thus result in higher mineralization as observed in aging ERRaKO mice. 
ERRa Deficiency Protects Females from Bone Loss Resulting from Sex Hormone Ablation
Normal aging causes a moderate bone loss as the result of a progressive imbalance between bone formation and bone resorption. This equilibrium is also disrupted in favor of bone resorption upon sex hormone deficiency which leads to a severe bone loss, as can be observed in women after menopause or in mice after ovariectomy. Since bone formation is more elevated in ERRaKO we hypothesized that this phenomenon might compensate for the remodeling imbalance induced by sex-hormone withdrawal. Gonadectomized wild type females showed an important decrease of relative bone volume (Fig. 4A ) and trabecular number (Fig. 4B) four wks after surgery. Strikingly, none of these parameters were significantly affected in ovariectomized ERRaKO animals, indicating that cancellous bone was preserved in mutant mice. Bone formation rate was enhanced in wt females as marker of enhanced bone remodeling (Fig. 4C) . In contrast, this parameter did not vary in ERRaKO mice according to the hormonal status. In males, orchidectomy resulted in similar variations in mineral density, bone volume and trabecular number in wild type and mutant mice (Table 1) , indicating suggesting that bone was equally affected, independently of the genotype. We thus concluded that the absence of ERRa completely protects against the bone loss induced by deficiency in sex hormone action in females, but not in males.
The mechanisms responsible for this phenomenon are not identified but it is tempting to speculate that i) the higher differentiation capacities of MSCs in osteoblasts in the absence of ERRa as well as ii) the low expression of opn in ERRaKO osteoblasts could be involved in sparing bone under estrogen deficiency challenge. Indeed, it has been shown that opn-deficient mice are resistant to ovariectomy-induced bone loss [37] .
In summary, our data show that the absence of ERRa leads to a resistance in age-as well as estrogen-deficiency-dependent bone loss exclusively in female mice. This finding may have important consequences for the treatment of osteoporosis following menopause, and will need careful investigation to unravel the mechanisms through which ERRa acts in osteoblast differentiation and bone mineralization in vivo.
Materials and Methods

Animals
ERRaKO animals have been described elsewhere [38] . All animal experiments were performed in the Plateau de Biologie Experimentale de la Souris (PBES; ENS Lyon) under Animal care procedures, conducted in accordance with the guidelines set by the European Community Council Directives (86/609/EEC) and approved by the local ethical committee. Animals were in C57black6 background and, except were stated, had access to food and water ad libitum. Mice were sacrificed by cervical dislocation at 10 a.m.
For surgery, animals were anesthetized with sodium pentobarbital. Testes were ligatured and cut through an incision in the scrotum. Ovaries were removed through an incision in the flanks. Animals were sacrificied 4 wk after operation. Statistical significance was analyzed using one-way ANOVA.
X-ray Micro-Computed Tomography Analysis
3D microarchitecture of the femur was evaluated using a highresolution (8 mm) microtomographic imaging system (eXplore Locus, GE, USA). A 3D region within the secondary spongiosa in the proximal metaphysis of the femur was reconstructed, beginning 500 mm proximal to the growth plate and extending to 1.5 mm. Cortical bone was reconstructed from a 1 mm thick region of interest centered on the diaphysis, 5 mm distal from the proximal growth plate. Morphometric parameters were computed using the Advanced Bone Analysis Microview Software (GE).
Histomorphometric Analysis
For histological analyses, undecalcified bones were fixed, deshydrated in ethanol solutions at 4uC and embedded in methyl-methacrylate according to standard protocols. For each femur, 7 mm thick longitudinal sections, parallel to the sagittal plane, were prepared. Bone sections were stained with von Kossa/ van Giseon reagent, images were captured using a Nikon eclipse 80i microscope and analyzed using NIS Elements AR 2.30 software (Nikon). To determine bone formation parameters, calcein (10 mg/kg body weight) was injected to mice i.p. 5 and 2 d before sacrifice. Bone formation rate was calculated as interlabeled widths/interval time. To determine bone resorption parameters, sections were stained for tartrate-resistant acid phosphatase (TRAP). TRAP-positive multinucleated cells attached to bone were scored as osteoclasts and results were expressed as number of osteoclasts per trabecular bone perimeter. Bone-related degradation products from Collagen 1 (Ctx) in serum were measured by immunosorbent assay, using a RatLaps ELISA kit from Nordic Bioscience Diagnostics A/S (Herlev, Denmark), following the recommendations of the manufacturers. Measurements were performed after overnight fasting.
Bone Marrow Cultures
Primary MSCs were collected from bone marrow of femur and tibia of 12-week old mice and cultured in six-well dishes (4610 6 cells/well) in MEMa containing 10% fetal calf serum with 100 U/ml penicillin G and 100 mg/ml streptomycin. For osteoblastic differentiation, after 5 d of culture the medium was supplemented with 50 mg/ml L-ascorbic acid and 10 mM bglycerophosphate and replaced every 2 to 3 days for 3, 7, 14 or 21 days. Osteoblastic differentiation was evaluated by ALP staining and ALP enzymatic activity. For ALP staining, cells were rinsed twice with PBS, and then fixed with 4% (v/v) formaldehyde for 5 min. After 3 washes with H 2 O, cells were incubated 30 min with Fast Blue RR salt and Naphtol AS-MX Phosphate Alkaline solution 0,25% (Sigma Aldrich) in the dark. For ALP enzymatic activity measurement, cells were lysed with Lysis Buffer (50 mM Tris, HCl pH 7,5; 0,1% Triton-X100; 0,9% NaCl). Cell lysates were incubated with 0,2 M of Naphtol Alkaline solution (Sigma Aldrich) and the conversion of p-nitrophenyl phosphate to pnitrophenol was spectrophotometrically determined and normalized to cellular protein content by using detergent compatible Bradford reagent (Pierce). For proliferation tests, viable cells were visually counted after resuspension and trypan blue coloration. Adenoviral vectors expressing GFP or ERRa have been previously described [39] and kindly donated by Anastasia Kralli.
Expression Analysis
RNAs were purified using Guanidinium thiocyanate/phenol/ chloroforme extraction. Total RNAs were reverse transcribed using Superscript II retrotranscription kit (Invitrogen). Quantitative PCR were performed using the SYBR GREEN Jump Start kit (Sigma Aldrich) in duplicate on an ABI apparatus using standard procedure. Expression data were normalized to the expression of the 36b4 housekeeping gene. Sequence of the primers used in this study:
36b4 
